Xenetic

$1.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (1.63%) Today
+$0.07 (3.74%) As of 7:34 PM EDT after-hours

Why Robinhood?

You can buy or sell Xenetic and other stocks, options, ETFs, and crypto commission-free!

About XBIO

Xenetic Biosciences, Inc. engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. Read More It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Employees
4
Headquarters
Framingham, Massachusetts
Founded
2011
Market Cap
1.63M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
258.98K
High Today
$1.93
Low Today
$1.81
Open Price
$1.88
Volume
231.25K
52 Week High
$54.60
52 Week Low
$1.54

Collections

XBIO News

BenzingaAug 15

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

239

XBIO Earnings

-$1.56
-$0.87
-$0.17
$0.52
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
-$1.56 per share

More XBIO News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.